Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Among HIV-Negative Participants Using Tenofovir/Emtricitabine-Based Preexposure Prophylaxis in 2020: A Substudy of the French National Agency for Research on AIDS and Viral Hepatitis PREVENIR and Inserm SAPRIS-Sero Cohorts | Zendy

Constance Delaugerre | Zendy; Lambert Assoumou | Zendy; Sarah Maylin | Zendy; Marine Minier | Zendy; Audrey Gabassi | Zendy; Michèle Genin | Zendy; Lydie Béniguel | Zendy; Jade Ghosn | Zendy; Xavier de Lamballerie | Zendy; Mayssam El Mouhebb | Zendy; Dominique Costagliola | Zendy; Fabrice Carrat | Zendy; JeanMichel Molina | Zendy

Open Access

Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Among HIV-Negative Participants Using Tenofovir/Emtricitabine-Based Preexposure Prophylaxis in 2020: A Substudy of the French National Agency for Research on AIDS and Viral Hepatitis PREVENIR and Inserm SAPRIS-Sero Cohorts

Author(s) -

Constance Delaugerre,

Lambert Assoumou,

Sarah Maylin,

Marine Minier,

Audrey Gabassi,

Michèle Genin,

Lydie Béniguel,

Jade Ghosn,

Xavier de Lamballerie,

Mayssam El Mouhebb,

Dominique Costagliola,

Fabrice Carrat,

JeanMichel Molina

Publication year - 2022

Publication title -

open forum infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.546

H-Index - 35

ISSN - 2328-8957

DOI - 10.1093/ofid/ofac188

Subject(s) - emtricitabine , medicine , tenofovir , seroprevalence , pre exposure prophylaxis , population , cohort , virology , human immunodeficiency virus (hiv) , immunology , antibody , viral load , men who have sex with men , environmental health , antiretroviral therapy , serology , syphilis

The potential preventive efficacy of tenofovir/emtricitabine on SARS-CoV-2 infection was assessed in HIV pre-exposition prophylaxis (PrEP) users. Prevalence of SARS-CoV-2 IgG between May and October 2020 was similar in PrEP users and in a matched population-based cohort suggesting that tenofovir/emtricitabine has no role in reducing the risk of SARS-CoV-2 acquisition.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research